$2.37 Billion is the total value of Artal Group S.A.'s 105 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BABA | New | ALIBABA GROUP HLDG LTDcall | $77,792,000 | – | 400,000 | +100.0% | 3.29% | – |
| QURE | New | UNIQURE NV | $54,568,000 | – | 1,150,000 | +100.0% | 2.31% | – |
| BAC | New | BK OF AMERICA CORPcall | $42,460,000 | – | 2,000,000 | +100.0% | 1.79% | – |
| BDTX | New | BLACK DIAMOND THERAPEUTICS I | $42,328,000 | – | 1,696,517 | +100.0% | 1.79% | – |
| XBI | New | SPDR SER TRcall | $38,720,000 | – | 500,000 | +100.0% | 1.64% | – |
| SDGR | New | SCHRODINGER INC | $38,698,000 | – | 897,445 | +100.0% | 1.64% | – |
| XLI | New | SELECT SECTOR SPDR TRcall | $35,406,000 | – | 600,000 | +100.0% | 1.50% | – |
| MA | New | MASTERCARD INCcall | $24,156,000 | – | 100,000 | +100.0% | 1.02% | – |
| ARWR | New | ARROWHEAD PHARMACEUTICALS IN | $17,262,000 | – | 600,000 | +100.0% | 0.73% | – |
| PRNB | New | PRINCIPIA BIOPHARMA INC | $14,845,000 | – | 250,000 | +100.0% | 0.63% | – |
| VNET | New | 21VIANET GROUP INCsponsored ads | $13,860,000 | – | 1,000,000 | +100.0% | 0.59% | – |
| TCOM | New | TRIP COM GROUP LTDads | $10,904,000 | – | 465,000 | +100.0% | 0.46% | – |
| AUPH | New | AURINIA PHARMACEUTICALS INC | $10,883,000 | – | 750,000 | +100.0% | 0.46% | – |
| MLCO | New | MELCO RESORTS AND ENTMNT LTDcall | $6,200,000 | – | 500,000 | +100.0% | 0.26% | – |
| ADVM | New | ADVERUM BIOTECHNOLOGIES INC | $5,862,000 | – | 600,000 | +100.0% | 0.25% | – |
| STOK | New | STOKE THERAPEUTICS INC | $5,725,000 | – | 250,000 | +100.0% | 0.24% | – |
| IMAB | New | I MABsponsored ads | $4,550,000 | – | 350,000 | +100.0% | 0.19% | – |
| New | TRILLIUM THERAPEUTICS INC | $4,040,000 | – | 1,000,000 | +100.0% | 0.17% | – | |
| PASG | New | PASSAGE BIO INC | $3,938,000 | – | 250,000 | +100.0% | 0.17% | – |
| EPZM | New | EPIZYME INCcall | $3,878,000 | – | 250,000 | +100.0% | 0.16% | – |
| APTX | New | APTINYX INC | $3,600,000 | – | 1,666,666 | +100.0% | 0.15% | – |
| SYRS | New | SYROS PHARMACEUTICALS INC | $3,001,000 | – | 506,138 | +100.0% | 0.13% | – |
| PRVL | New | PREVAIL THERAPEUTICS INC | $2,438,000 | – | 200,000 | +100.0% | 0.10% | – |
| PTLA | New | PORTOLA PHARMACEUTICALS INC | $1,426,000 | – | 200,000 | +100.0% | 0.06% | – |
| RIGL | New | RIGEL PHARMACEUTICALS INC | $546,000 | – | 350,000 | +100.0% | 0.02% | – |
| LPTX | New | LEAP THERAPEUTICS INC | $395,000 | – | 250,000 | +100.0% | 0.02% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-05-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AGENUS INC | 42 | Q3 2023 | 1.9% |
| IRONWOOD PHARMACEUTICALS INC | 42 | Q3 2023 | 0.3% |
| ALNYLAM PHARMACEUTICALS INC | 37 | Q3 2023 | 5.1% |
| LEXICON PHARMACEUTICALS INC | 34 | Q3 2023 | 20.6% |
| AMICUS THERAPEUTICS INC | 30 | Q3 2023 | 2.7% |
| BEIGENE LTD | 28 | Q3 2023 | 7.4% |
| BK OF AMERICA CORP | 28 | Q1 2021 | 4.3% |
| SAGE THERAPEUTICS INC | 28 | Q2 2023 | 1.9% |
| AGIOS PHARMACEUTICALS INC | 28 | Q2 2020 | 1.1% |
| NEKTAR THERAPEUTICS | 27 | Q2 2020 | 1.3% |
View Artal Group S.A.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| WEIGHT WATCHERS INTERNATIONAL INC | February 13, 2015 | 29,443,300 | 51.9% |
View Artal Group S.A.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR/A | 2024-05-17 |
| 4 | 2024-05-14 |
| 13F-HR | 2024-05-13 |
| 4 | 2024-03-25 |
| 4 | 2024-03-13 |
| 4 | 2024-02-29 |
| 13F-HR | 2024-02-09 |
| 13F-HR | 2023-11-13 |
| 4 | 2023-10-16 |
| 13F-HR | 2023-08-11 |
View Artal Group S.A.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.